Oncocyte (NASDAQ:IMDX) Issues Earnings Results

Oncocyte (NASDAQ:IMDX) announced its earnings results on Monday. The company reported ($0.23) EPS for the quarter, FiscalAI reports. The company had revenue of $0.24 million during the quarter.

Here are the key takeaways from Oncocyte’s conference call:

• FDA marketing authorization remains targeted for later this year for GraftAssureDx. The company said the FDA’s information requests appeared routine and addressable, with an SIR meeting planned to align on the response before resubmission, though timing remains outside its control.
• Medicare’s expanded MolDX coverage, increasing potential kidney-transplant surveillance testing from eight to 14 tests in the first three years, could improve the economic case for in-house testing. Management believes this could expand its stated $2 billion TAM as testing frequency, therapy monitoring, and additional organ indications grow.
• Head-to-head data showed clinical equivalence to leading centralized laboratory assays, driving interest from major U.S. transplant centers and reference labs. More than half of the top 10 U.S. transplant centers are engaged through the FDA program or registry, and management believes it has roughly a two-year lead in kitted product development.
• Second-quarter cash burn was $10 million, and the company now expects approximately $8 million of quarterly cash burn in the second half of the year, above its prior $6 million estimate. Higher spending reflects regulatory completion costs, registry activities, and preparations for commercial launch, although management said it is evaluating ways to extend its runway.
• European regulatory progress appears favorable, with IVDR submission still targeted for the second half of the year and U.K. self-certification expected to be easier. However, broader European adoption remains dependent on reimbursement expansion and clinical catalysts such as routine approval of anti-CD38 therapies.

Oncocyte Stock Down 1.2%

Shares of NASDAQ IMDX opened at $4.77 on Tuesday. Oncocyte has a 52 week low of $2.33 and a 52 week high of $8.51. The stock has a market capitalization of $154.02 million, a price-to-earnings ratio of -3.22 and a beta of 1.79. The firm has a 50-day simple moving average of $5.21 and a 200-day simple moving average of $5.14.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IMDX. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Oncocyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Oncocyte currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.